Article
Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Dec 1998
Febbo P G, Kantoff P W, Giovannucci E, Brown M, Chang G, Hennekens C H, Stampfer M
Abstract excerpt
The p450 hepatic microsomal enzyme system metabolizes exogenous drugs and carcinogens. Debrisoquine hydroxylase (CYP2D6), one member of the p450 hemoproteins, has polymorphic expression leading to poor metabolism of debrisoquine and similar compounds in approximately 7% of Caucasians. The genetic...
Topics
- Adult
- Aged
- Aged, 80 and over
- Alleles
- Case-Control Studies
- Cytochrome P-450 CYP2D6
- DNA Primers
- DNA, Neoplasm
- Debrisoquin
- Female
- Gene Expression Regulation, Enzymologic
- Humans
- Male
- Middle Aged
- Mutation
- Odds Ratio
- Phenotype
- Polymerase Chain Reaction